Endometriosis is a chronic, inflammatory disease that affects the uterus and other pelvic organs. It is characterized by the presence of endometrial tissue outside of the uterus, which can lead to pain and infertility. The global endometriosis market was valued at USD 3.2 billion in 2018 and is expected to reach USD 4.5 billion by 2030, growing at a CAGR of 5.6% from 2019 to 2030. Gonadotropins releasing hormone agonists (GnRH-a) are expected to be the fastest-growing segment during the forecast period due to their efficacy in treating endometriosis symptoms such as pain and infertility caused by this condition. The global endometriosis market has been segmented on the basis of type into gonadotropins releasing hormone agonists (GnRH-a), nonsteroidal antiinflammatory drugs (NSAIDs), progestin, oral contraceptive pills; on application into hospital use and clinic use; and on region into North America, Latin America, Europe, Asia Pacific & Middle East & Africa regions respectively for better understanding of this market across different geographies with respect to various segments such as type, application etc, along with their respective growth rates over time for each region/segment from 2021-2030. 5a) The use of hormonal birth control methods has been linked to an increase in risk for developing endometriosis; however, it can also be used as a treatment option for those diagnosed with this condition by suppressing ovulation or preventing implantation on the uterine wall (depending on type). 5b) Hormonal birth control methods can also be used to treat symptoms associated with endometriosis such as pain during menstruation or pelvic pain by reducing inflammation and relieving pressure on pelvic organs that may cause discomfort during periods or sex (depending on type).
- The number of women with endometriosis is increasing.
- Women are delaying childbirth and having children later in life, which increases the risk of endometriosis.
- Endometriosis is more common in women who have had a hysterectomy or tubal ligation, which has increased the number of people with endometriosis over time as well as the number of people who are infertile due to these surgeries.
- There is an increased awareness about endometriosis and its symptoms, which may lead to more diagnoses and treatment options for patients with this condition.
Industry Growth Insights published a new data on “Endometriosis Market”. The research report is titled “Endometriosis Market research by Types (Gonadotropins Releasing Hormone Agonists, Non-Steroidal Anti-Inflammatory Drugs, Progestin, Oral Contraceptive Pills), By Applications (Hospital Use, Clinic Use, Other), By Players/Companies AbbVie, AstraZeneca, Bayer HealthCare, Pfizer, Addex Therapeutics, Astellas Pharma, Debiopharm, ElexoPharm, EndoCeutics, Euroscreen, Forendo Pharma, Kissei Pharmaceutical, Neurocrine Biosciences, Nippon Shinyaku, Takeda, Bayer AG, Neurocrine Biosciences”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Endometriosis Market Research Report
By Type
Gonadotropins Releasing Hormone Agonists, Non-Steroidal Anti-Inflammatory Drugs, Progestin, Oral Contraceptive Pills
By Application
Hospital Use, Clinic Use, Other
By Companies
AbbVie, AstraZeneca, Bayer HealthCare, Pfizer, Addex Therapeutics, Astellas Pharma, Debiopharm, ElexoPharm, EndoCeutics, Euroscreen, Forendo Pharma, Kissei Pharmaceutical, Neurocrine Biosciences, Nippon Shinyaku, Takeda, Bayer AG, Neurocrine Biosciences
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Endometriosis Market Report Segments:
The global Endometriosis market is segmented on the basis of:
Types
Gonadotropins Releasing Hormone Agonists, Non-Steroidal Anti-Inflammatory Drugs, Progestin, Oral Contraceptive Pills
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Use, Clinic Use, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- AstraZeneca
- Bayer HealthCare
- Pfizer
- Addex Therapeutics
- Astellas Pharma
- Debiopharm
- ElexoPharm
- EndoCeutics
- Euroscreen
- Forendo Pharma
- Kissei Pharmaceutical
- Neurocrine Biosciences
- Nippon Shinyaku
- Takeda
- Bayer AG
- Neurocrine Biosciences
Highlights of The Endometriosis Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Gonadotropins Releasing Hormone Agonists
- Non-Steroidal Anti-Inflammatory Drugs
- Progestin
- Oral Contraceptive Pills
- By Application:
- Hospital Use
- Clinic Use
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Endometriosis Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Endometriosis is a condition in which the tissue that lines the inside of the uterus (the endometrium) grows outside of it. This growth can occur anywhere on or near the uterine wall, including within and around the fallopian tubes. The endometrium can also grow on other parts of your body, such as your ovaries or bladder.
Some of the key players operating in the endometriosis market are AbbVie, AstraZeneca, Bayer HealthCare, Pfizer, Addex Therapeutics, Astellas Pharma, Debiopharm, ElexoPharm, EndoCeutics, Euroscreen, Forendo Pharma, Kissei Pharmaceutical, Neurocrine Biosciences, Nippon Shinyaku, Takeda, Bayer AG, Neurocrine Biosciences.
The endometriosis market is expected to register a CAGR of 5.6%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Endometriosis Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Endometriosis Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Endometriosis Market - Supply Chain
4.5. Global Endometriosis Market Forecast
4.5.1. Endometriosis Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Endometriosis Market Size (000 Units) and Y-o-Y Growth
4.5.3. Endometriosis Market Absolute $ Opportunity
5. Global Endometriosis Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Endometriosis Market Size and Volume Forecast by Type
5.3.1. Gonadotropins Releasing Hormone Agonists
5.3.2. Non-Steroidal Anti-Inflammatory Drugs
5.3.3. Progestin
5.3.4. Oral Contraceptive Pills
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Endometriosis Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Endometriosis Market Size and Volume Forecast by Application
6.3.1. Hospital Use
6.3.2. Clinic Use
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Endometriosis Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Endometriosis Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Endometriosis Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Endometriosis Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Endometriosis Demand Share Forecast, 2019-2026
9. North America Endometriosis Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Endometriosis Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Endometriosis Market Size and Volume Forecast by Application
9.4.1. Hospital Use
9.4.2. Clinic Use
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Endometriosis Market Size and Volume Forecast by Type
9.7.1. Gonadotropins Releasing Hormone Agonists
9.7.2. Non-Steroidal Anti-Inflammatory Drugs
9.7.3. Progestin
9.7.4. Oral Contraceptive Pills
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Endometriosis Demand Share Forecast, 2019-2026
10. Latin America Endometriosis Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Endometriosis Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Endometriosis Market Size and Volume Forecast by Application
10.4.1. Hospital Use
10.4.2. Clinic Use
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Endometriosis Market Size and Volume Forecast by Type
10.7.1. Gonadotropins Releasing Hormone Agonists
10.7.2. Non-Steroidal Anti-Inflammatory Drugs
10.7.3. Progestin
10.7.4. Oral Contraceptive Pills
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Endometriosis Demand Share Forecast, 2019-2026
11. Europe Endometriosis Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Endometriosis Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Endometriosis Market Size and Volume Forecast by Application
11.4.1. Hospital Use
11.4.2. Clinic Use
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Endometriosis Market Size and Volume Forecast by Type
11.7.1. Gonadotropins Releasing Hormone Agonists
11.7.2. Non-Steroidal Anti-Inflammatory Drugs
11.7.3. Progestin
11.7.4. Oral Contraceptive Pills
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth rojections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Endometriosis Demand Share, 2019-2026
12. Asia Pacific Endometriosis Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Endometriosis Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Endometriosis Market Size and Volume Forecast by Application
12.4.1. Hospital Use
12.4.2. Clinic Use
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Endometriosis Market Size and Volume Forecast by Type
12.7.1. Gonadotropins Releasing Hormone Agonists
12.7.2. Non-Steroidal Anti-Inflammatory Drugs
12.7.3. Progestin
12.7.4. Oral Contraceptive Pills
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Endometriosis Demand Share, 2019-2026
13. Middle East & Africa Endometriosis Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Endometriosis Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Endometriosis Market Size and Volume Forecast by Application
13.4.1. Hospital Use
13.4.2. Clinic Use
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Endometriosis Market Size and Volume Forecast by Type
13.7.1. Gonadotropins Releasing Hormone Agonists
13.7.2. Non-Steroidal Anti-Inflammatory Drugs
13.7.3. Progestin
13.7.4. Oral Contraceptive Pills
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Endometriosis Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Endometriosis Market: Market Share Analysis
14.2. Endometriosis Distributors and Customers
14.3. Endometriosis Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AbbVie
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. AstraZeneca
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bayer HealthCare
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Pfizer
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Addex Therapeutics
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Astellas Pharma
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Debiopharm
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. ElexoPharm
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. EndoCeutics
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Euroscreen
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Forendo Pharma
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Kissei Pharmaceutical
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Neurocrine Biosciences
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Nippon Shinyaku
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Takeda
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Bayer AG
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Neurocrine Biosciences
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook